AngioDynamics, Inc. (NASDAQ:ANGO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $18.6667.

A number of equities research analysts have issued reports on ANGO shares. Canaccord Genuity Group lowered their target price on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Finally, Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th.

AngioDynamics Trading Down 0.3%

AngioDynamics stock opened at $11.92 on Monday. AngioDynamics has a 12 month low of $8.36 and a 12 month high of $13.99. The business’s 50 day simple moving average is $10.83 and its 200 day simple moving average is $11.42. The company has a market cap of $492.53 million, a price-to-earnings ratio of -15.89 and a beta of 0.37.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The business had revenue of $78.42 million for the quarter, compared to the consensus estimate of $76.77 million. As a group, equities research analysts forecast that AngioDynamics will post -0.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in AngioDynamics by 262.7% during the 1st quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier’s stock valued at $5,726,000 after acquiring an additional 364,763 shares during the period. Quantinno Capital Management LP raised its holdings in AngioDynamics by 15.0% during the 1st quarter. Quantinno Capital Management LP now owns 43,539 shares of the medical instruments supplier’s stock valued at $495,000 after acquiring an additional 5,675 shares during the period. Lazard Asset Management LLC raised its holdings in AngioDynamics by 1,328.2% during the 1st quarter. Lazard Asset Management LLC now owns 154,578 shares of the medical instruments supplier’s stock valued at $1,758,000 after acquiring an additional 143,755 shares during the period. Paradigm Capital Management Inc. NY raised its holdings in AngioDynamics by 5.9% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 718,200 shares of the medical instruments supplier’s stock valued at $8,166,000 after acquiring an additional 40,000 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in AngioDynamics by 0.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock valued at $8,624,000 after acquiring an additional 5,509 shares during the period. Institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.